尼莫地平联合阿托伐他汀钙对血管性痴呆患者SOD活性和血脂水平的影响

目的:研究尼莫地平联合阿托伐他汀钙对血管性痴呆患者超氧化物歧化酶(Superoxide dismutase,SOD)活性和血脂水平的影响。方法:选择2017年1月～2019年1月我院收治的95例血管性痴呆患者,随机分为两组。对照组口服尼莫地平治疗,每次30 mg,每天3次;观察组在服用尼莫地平的基础上,加服阿托伐他汀钙治疗,每次20 mg,每天1次。比较两组治疗前后的SOD活性和血脂水平。结果:观察组的总有效率高于对照组(P0.05);治疗后,两组的日常生活能力量表(Activity of daily living scale,ADL)和简易精神状态评价量表(Mini-mental state examination,MMSE)评分均升高(P0.05),且观察组的高于对照组(P0.05);治疗后,两组的SOD活性升高(P0.05),且观察组高于对照组(P0.05);治疗后,两组的高密度脂蛋白胆固醇(High-density lipoprotein cholesterol,HDL-C)均明显升高(P0.05),甘油三酯(Triglyceride,TG)、低密度脂蛋白胆固醇(Low-density lipoprotein cholesterol,LDL-C)和总胆固醇(Total Cholesterol,TC)均明显降低(P0.05),且上述指标的变化程度观察组优于对照组(P0.05)。结论:尼莫地平联合阿托伐他汀钙能明显提高血管性痴呆患者的SOD活性,改善血脂水平,改善智能认知能力和生活能力。

Effect of Nimodipine Combined with Atorvastatin Calcium on SOD Activity and Lipid Level in Patients with Vascular Dementicui

ABSTRACT Objective: To study the effect of nimodipine combined with atorvastatin calcium on SOD activity and lipid level in patients with vascular dementia. Methods: Selected 95 cases of patients with vascular dementia who were treated in our hospital from January 2017 to January 2019, divided into two groups randomly. The control group took nimodipine orally, 30 mg each time, three times a day; the observation group took atorvastatin calcium on the basis of nimodipine, 20 mg each time, once a day. The SOD activity and blood lipid levels were compared between the two groups before and after treatment. Results: The total effective rate of the observation group was significantly higher than control group (P<0.05). After treatment, the ADL and MMSE scores of the two groups were significantly increased (P<0.05), and the observation group were significantly higher than those of the control group (P<0.05). After treatment, the SOD activity of the two groups increased significantly (P<0.05), and the observation group was significantly higher than that of the control group (P<0.05). After treatment, HDL-C in the two groups increased significantly (P<0.05), TG, LDL-C and TC decreased significantly (P<0.05), and the above indicator for the observation group is superior to the control group (P<0.05). Conclusion: Nimodipine combined with atorvastatin calcium can significantly improve SOD activity, blood lipid level, cognitive function and living ability in patients with vascular dementia.